×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VIR – vir biotechnology, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VIR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
03:27 am
vir
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology [Yahoo! Finance]
Medium
Report
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology [Yahoo! Finance]
12/16
04:42 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/16
04:36 pm
vir
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program [Yahoo! Finance]
Medium
Report
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program [Yahoo! Finance]
12/16
04:05 pm
vir
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Medium
Report
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
12/2
03:47 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/25
01:59 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/19
04:05 pm
vir
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
11/18
10:50 am
vir
Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]
Low
Report
Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
04:25 pm
vir
Form 8-K Vir Biotechnology, Inc. For: Dec 16
Medium
Report
Form 8-K Vir Biotechnology, Inc. For: Dec 16
12/3
04:30 pm
vir
Form 4 Vir Biotechnology, Inc. For: Dec 01 Filed by: SVF Endurance (Cayman) Ltd
High
Report
Form 4 Vir Biotechnology, Inc. For: Dec 01 Filed by: SVF Endurance (Cayman) Ltd
12/2
07:48 pm
vir
Form 4 Vir Biotechnology, Inc. For: Dec 01 Filed by: SATO VICKI L
High
Report
Form 4 Vir Biotechnology, Inc. For: Dec 01 Filed by: SATO VICKI L
12/1
04:30 pm
vir
Form 4 Vir Biotechnology, Inc. For: Nov 26 Filed by: SVF Endurance (Cayman) Ltd
Low
Report
Form 4 Vir Biotechnology, Inc. For: Nov 26 Filed by: SVF Endurance (Cayman) Ltd
11/26
04:31 pm
vir
Form 4 Vir Biotechnology, Inc. For: Nov 24 Filed by: SVF Endurance (Cayman) Ltd
Low
Report
Form 4 Vir Biotechnology, Inc. For: Nov 24 Filed by: SVF Endurance (Cayman) Ltd
11/25
09:00 pm
vir
Form 144 Vir Biotechnology, Inc. Filed by: SVF Endurance (Cayman) Ltd
Low
Report
Form 144 Vir Biotechnology, Inc. Filed by: SVF Endurance (Cayman) Ltd
11/18
02:47 pm
vir
Form 4 Vir Biotechnology, Inc. For: Nov 17 Filed by: O'Byrne Jason
Low
Report
Form 4 Vir Biotechnology, Inc. For: Nov 17 Filed by: O'Byrne Jason
11/17
03:20 pm
vir
Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason
Low
Report
Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/25
CDC Issues Warnings on Virus; Markets Take Hit: Virus Update [Yahoo! Finance News]
61.4%
2/27 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. 58.5%
3/13 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. 21.3%
4/6 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions 21.1%
3/13 Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC] 14.1%
2/25 CDC Tells Americans to Start Readying for Outbreak: Virus Update [Yahoo! Finance News] 12.9%
1/15 Vir Biotechnology (VIR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] 12.5%
3/10 Vir Biotechnology to Present at Barclays Global Healthcare Conference 10.0%
3/26 Q4/2019 12/31/2019 EPS -0.710 ZacksConsensus -0.470 ActVsEst (0.240) - Miss 7.2%
10/18 Form 4 Vir Biotechnology, Inc. For: Oct 16 Filed by: Fullerton Management Pte Ltd 5.5%
2/27 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. 58.5%
3/13 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. 21.3%
4/6 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions 21.1%
3/13 Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC] 14.1%
2/25 CDC Tells Americans to Start Readying for Outbreak: Virus Update [Yahoo! Finance News] 12.9%
1/15 Vir Biotechnology (VIR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] 12.5%
3/10 Vir Biotechnology to Present at Barclays Global Healthcare Conference 10.0%
3/26 Q4/2019 12/31/2019 EPS -0.710 ZacksConsensus -0.470 ActVsEst (0.240) - Miss 7.2%
10/18 Form 4 Vir Biotechnology, Inc. For: Oct 16 Filed by: Fullerton Management Pte Ltd 5.5%
TOP News Decliners
2/28
Trending Ticker: VIR Surges as Coronavirus fears persist [Yahoo! Finance News]
-35.9%
3/9 Form 8-K Vir Biotechnology, Inc. For: Mar 03 -22.1%
4/7 Biotechs Working Closely & Feverishly With CDC for COVID-19 Vaccine Development -14.4%
3/6 Why Was Vir Biotechnology Up 74% in February? [The Motley Fool] -14.2%
10/10 Form 3 Vir Biotechnology, Inc. For: Oct 10 Filed by: Platinum International Investment Holding RSC Ltd -13.2%
4/8 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 -11.2%
3/19 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. -10.8%
2/12 Form 8-K Vir Biotechnology, Inc. For: Feb 12 -10.2%
3/25 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 -8.5%
4/6 GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters] -8.2%
3/9 Form 8-K Vir Biotechnology, Inc. For: Mar 03 -22.1%
4/7 Biotechs Working Closely & Feverishly With CDC for COVID-19 Vaccine Development -14.4%
3/6 Why Was Vir Biotechnology Up 74% in February? [The Motley Fool] -14.2%
10/10 Form 3 Vir Biotechnology, Inc. For: Oct 10 Filed by: Platinum International Investment Holding RSC Ltd -13.2%
4/8 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 -11.2%
3/19 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. -10.8%
2/12 Form 8-K Vir Biotechnology, Inc. For: Feb 12 -10.2%
3/25 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 -8.5%
4/6 GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters] -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: